RPL37

Across TCGA pan-cancer cohorts, RPL37 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RPL37 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RPL37 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RPL37 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, HNSC, and COAD are the cancer types where RPL37 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.855	0.650	.001	28	view →
HNSC	DFS	Median	II,III,IV	0.862	0.669	.012	16	view →
COAD	DFS	Median	III,IV	1.000	0.895	.039	12	view →
LSCC	OS	Quartile	II,III,IV	0.919	0.637	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RPL37–PDAC (DFS)

Open the PDAC breakdown →